electroCore, Inc. has initiated a clinical study evaluating the safety and efficacy of its gammaCore™ non-invasive vagus nerve stimulation (nVNS) device as an adjunct therapy for PTSD symptoms. The study, conducted in collaboration with Acacia Clinics and the Vagus Nerve Society, has enrolled its first eight patients, with a target of 40 participants over a 12-week treatment period. The primary endpoints focus on the incidence of serious adverse events and changes in the Clinician-Administered PTSD Scale (CAPS-5) total score.

This study is particularly significant given the limited treatment options currently available for PTSD, highlighting the potential of bioelectronic medicine to address both neurological and physiological aspects of the disorder. The primary efficacy endpoint will provide critical insights into the effectiveness of nVNS, while secondary endpoints will assess changes in PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The involvement of experienced researchers, such as Dr. Danielle DeSouza and Dr. Noah DeGaetano, underscores the robust scientific framework behind the study.

The findings from this trial could shift the landscape of PTSD treatment by establishing nVNS as a viable adjunctive therapy, potentially paving the way for broader applications of neuromodulation techniques in neuropsychiatric disorders. If successful, this could accelerate the development timelines for similar bioelectronic interventions and encourage further exploration into non-invasive therapies for other mental health conditions, addressing a critical unmet need in the field.

Source: globenewswire.com